Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Galapagos Pushes Bone and Joint Compounds Toward Phase I Trials

This article was originally published in The Pink Sheet Daily

Executive Summary

New agents could beat standard of care in bone cancer metastases and rheumatoid arthritis, firm says.

You may also be interested in...

Pharma-Size That: Galapagos Expands RA Drug Development With Blockbuster J&J Deal

Alliance valued at over €1 billion includes potential landmark €60 million license on Galapagos' lead internal rheumatoid arthritis candidate GT418.

Galapagos Seeks Partner For Recently Acquired Low-Dose Estrogen Product

The firm continues its acquisition program with the purchase of ProStrakan’s bone disease unit for a maximum value of $60 million.

Rare Disease Roundtable: Dealing With Pricing Pressure

Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts